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doi:10.1016/j.jmii.2011.01.037Background: The recent molecular epidemiological studies concerning epidemiological studies
concerning methicillin-resistant Staphylococcus aureus (MRSA) blood isolates from adult
patients and susceptibilities of MRSA isolates with high vancomycin minimum inhibitory
concentrations (MICs) (2 mg/L) to linezolid, tigecycline, and daptomycin in Taiwan remain
limited. The objectives of the study were (1) to better understand the change of molecular
epidemiology of MRSA blood isolates and (2) to evaluate the in vitro activity of new anti-
Gram-positive agents, including linezolid, tigecycline, and daptomycin.
Methods: A total of 470 nonduplicate MRSA blood isolates from adult patients (older than 18
years) were collected from January 2006 to December 2008. The MICs of these isolates to
various antibiotics were determined. Multilocus sequence typing was also performed in all
isolates.
Results: Three sequence types (STs) constitute most (92.1%) of these 470 MRSA isolates: ST239
(53.2%), ST59 (23.2%), and ST5 (15.7%). Throughout the 3-year study, the ST239 strain re-
mained predominant but with a significant trend of declining annually (pZ 0.03). In contrast,
the proportion of isolates of ST59 increased, although the increment was insignificant
(pZ 0.14). The proportion of MRSA isolates with a vancomycin MIC of 2 mg/L was 17.2%. All
of these isolates with a vancomycin MIC of 2 mg/L were susceptible to linezolid and tigecy-
cline, whereas most of them (98.8%) were susceptible to daptomycin.Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, No. 7,
aiwan.
tw (S.-C. Chang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Stratified analysis by vancomycin MIC 347Conclusions: ST239 remained predominant during the 3-year period but with a significant trend
of declining. Moreover, linezolid, tigecycline, and daptomycin remained highly active against
MRSA blood isolates, even with a vancomycin MIC of 2 mg/L.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The high prevalence of methicillin-resistant Staphylococcus
aureus (MRSA), accounting for up to 80% of all S. aureus
causing nosocomial infection, has been noted in Taiwan since
1998.1 Owing to the high transmissibility of MRSA,2 increased
prevalence of MRSA infectionsmight result from the spread of
the predominant endemic strains.3 Previous studies had
demonstrated a predominant MRSA strain within an institute,
although itmight change over the years; in addition, different
MRSA strains would have different antibiograms.4e6 Several
studies have also reported that the expanding community
reservoirs of community-associated MRSA (CA-MRSA) had
inevitably led tothe invasionofCA-MRSA strains intohospitals;
in addition, CA-MRSA strains may be replacing the traditional
health careeassociated MRSA (HA-MRSA) strains in the health
careeassociated infections.7e9
Among the clinical problems caused by MRSA, blood-
stream infection has received considerable attention owing
to its relatively high morbidity and mortality rates.
Although vancomycin has been served as the cornerstone of
treatment against serious MRSA infections in the past
decades, bacteremia and endocarditis caused by MRSA
cannot always be easily treated by vancomycin.2 Moreover,
several studies demonstrated an increased clinical failure
of the vancomycin therapy in patients with MRSA bacter-
emia, especially when the causative isolate had a higher
vancomycin minimum inhibitory concentration (MIC)
(2 mg/L).10,11 Under such clinical circumstances, newer
antimicrobial agents, for example, linezolid, tigecycline,
and daptomycin, have been used as alternatives to vanco-
mycin.12,13 However, susceptibilities of MRSA isolates with
high vancomycin MICs (2 mg/L) to linezolid, tigecycline,
and daptomycin, have not been thoroughly analyzed in
Taiwan. The objectives of the study were (1) to better
understand the change of molecular epidemiology of MRSA
blood isolates and (2) to evaluate the in vitro activity of
linezolid, tigecycline, and daptomycin, against MRSA
isolates with high vancomycin MICs (2 mg/L).
Methods
Bacterial isolates and definition
This study was performed at the National Taiwan University
Hospital, a major teaching hospital located in northern
Taiwan with a bed capacity of 2,200. Totally, 470 non-
duplicate blood isolates of MRSA from adult patients, older
than 18 years, were collected between January 2006 and
December 2008. All isolates were stored at 70C until the
subsequent microbiological tests were performed.
HA-MRSA infections were defined as the presence of any
of the following risk factors: (1) an MRSA infectionidentified after 48 hours of admission; (2) a previous
hospitalization, surgery, dialysis, or residence in a long-
term-care facility within 1 year of the MRSA culture date;
(3) the presence of a permanent indwelling catheter or
percutaneous medical device (e.g. tracheostomy tube,
gastrostomy tube, nephrostomy tubes, or biliary drains) at
the time of positive culture; or (4) a known previous posi-
tive culture for MRSA within 1 year of the study period.14,15
Community-onset MRSA (CO-MRSA) infection was defined as
an illness compatible with staphylococcal disease, in which
MRSA was recovered from the culture of specimens
obtained from the site of infection in an outpatient setting
or from an inpatient within 48 hours of admission.16 CA-
MRSA infections were defined by a community-onset
infection in the absence of any of the aforementioned
health careeassociated risk factors.16 The causative MRSA
isolates of CA-MRSA infections were defined as CA-MRSA
isolates. Conversely, the causative MRSA isolates of HA-
MRSA infections and CO-MRSA infections were defined as
HA-MRSA isolates and CO-MRSA isolates, respectively.
Antimicrobial susceptibility tests
The susceptibilities of these isolates to various antibiotics,
including erythromycin, clindamycin, minocycline, trime-
thoprimesulfamethoxazole (SXT), gentamicin, vancomycin,
linezolid, and tigecycline, were determined using the agar
dilution method based on the guidelines of the Clinical and
Laboratory Standards Institute.17 The susceptibility to
daptomycin was determined by the broth microdilution
method.17 The susceptibilities of erythromycin, clindamy-
cin, minocycline, SXT, gentamicin, ciprofloxacin, vanco-
mycin, linezolid, and daptomycin were interpreted
according to the Clinical and Laboratory Standards Institute
breakpoints.18 The susceptibility to tigecycline was deter-
mined based on the recommended breakpoints by the
European Committee for Antimicrobial Susceptibility
Testing.19 A breakpoint less than or equal to 0.5 mg/L was
determined to be tigecycline susceptible.19 Staphylococcus
aureus ATCC 29213 was used as the internal control for
each run of the susceptibility test.
Molecular typing
Preparation of chromosomal DNA was described previ-
ously.19 All isolates were tested by staphylococcal cassette
chromosome mec (SCCmec) element typing and multilocus
sequence typing.20
Statistical analysis
The Chi-squared test for trend was used to test the secular
change. The statistical analyses were performed using SAS
Table 1 The characteristics of the 470 MRSA blood isolates stratified by either infection types or STs
Characteristics Origin, n (%) Clonal type, n (%)
HA-MRSA CO-MRSA CA-MRSA ST239 ST59 ST5
Total isolates 337 (71.7) 124 (26.4) 9 (1.9) 250 (53.2) 109 (23.2) 74 (15.7)
SCCmec type
II 59 (17.5) 14 (11.3) 0 0 0 74 (100)
III 204 (60.5) 50 (40.3) 0 250 (100) 0 0
IV 50 (14.8) 35 (28.2) 6 (66.7) 0 65 (59.6) 0
V 24 (7.1) 25 (20.2) 3 (33.3) 0 44 (40.4) 0
Susceptible to
Erythromycin 14 (4.2) 17 (13.7) 1 (11.1) 0 10 (9.2) 0
Clindamycin 15 (4.5) 21 (16.9) 2 (22.2) 1 (0.4) 12 (11.0) 0
Minocycline 145 (43.0) 69 (55.6) 9 (100) 20 (8.0) 103 (94.5) 70 (94.6)
SXT 129 (38.3) 72 (58.1) 9 (100) 3 (1.2) 105 (96.3) 72 (97.3)
Gentamicin 47 (13.9) 43 (34.7) 5 (55.6) 4 (1.6) 79 (72.5) 4 (5.4)
Ciprofloxacin 66 (19.6) 53 (42.7) 9 (100) 1 (0.4) 104 (95.4) 0
CA-MRSAZ community-associated MRSA; CO-MRSAZ community-onset MRSA; HA-MRSAZ health careeassociated MRSA; MRSAZme-
thicillin-resistant Staphylococcus aureus; PVLZ PantoneValentine leukocidin; SCCmecZ staphylococcal cassette chromosome mec;
STZ sequence type; SXTZ trimethoprimesulfamethoxazole.
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Figure 1. The change in the proportion of ST239, ST59, and
ST5, among 470 methicillin-resistant Staphylococcus aureus
blood isolates, 2006e2008. STZ sequence type.
348 T.-M. Kao et al.statistical software (version 9.1; SAS Institute Inc., Cary, NC,
USA). A p value less than 0.05 was considered significant.
Results
Characteristics, molecular typing, and antibiograms
Among the 470 tested MRSA isolates, 337 (71.7%), 124
(26.4%), and 9 (1.9%) were classified into HA-MRSA, CO-
MRSA, and CA-MRSA isolates, respectively. Table 1
summarizes the distribution of SCCmec element, and mul-
tilocus sequence typing among the 470 isolates. The Type III
SCCmec element was the predominant element among HA-
MRSA (60.5%) and CO-MRSA (40.3%) isolates. However,
66.7% and 33.3% of CA-MRSA isolates carried the Type IV and
the Type V SCCmec elements, respectively.
Three sequence types (STs) constituted most of the 470
MRSA isolates (92.1%)dST239 (53.2%), ST59 (23.2%), and ST5
(15.7%). Similarly, three STs accounted for most of the 337
HA-MRSA isolates (93.8%)dST239 (58.8%), ST59 (17.8%), and
ST5 (17.2%). Among the nine CA-MRSA isolates, eight (88.9%)
were ST59 and one (11.1%) was ST8. All ST239 isolates (100%)
carried the Type III SCCmec element. In contrast, all ST5
isolates (100%) carried theType II SCCmecelement. Sixty-five
(59.6%) and44 (40.4%) isolates of ST59 carried theType IVand
the Type V SCCmec elements, respectively.
Most of the CA-MRSA isolates expressed resistance to both
erythromycin and clindamycin, but were susceptible to
minocycline, SXT, and ciprofloxacin. However, most HA-
MRSA isolates were multidrug resistant. Almost all ST59 and
ST5 isolates were susceptible to minocycline and SXT, but
resistant to erythromycin and clindamycin. Interestingly,
although almost all ST59 isolates were also susceptible to
ciprofloxacin, all ST5 isolateswere resistant to ciprofloxacin.
Gentamicin susceptibility rates of ST59 and ST5 isolateswere
72.5% and 5.4%, respectively. With regard to ST239 isolates,
almost all strains were resistant to erythromycin, clindamy-
cin, minocycline, SXT, gentamicin, and ciprofloxacin.Change in the proportion of ST239, ST59, and ST5,
from 2006 to 2008
Figure 1 demonstrates the change in the proportion of ST239,
ST59, and ST5 isolates among the tested 470 MRSA blood
isolates. The proportion of ST5 isolates remained stable
(pZ 0.77). Conversely, although the proportion of ST59
isolates increasedduring the3-year period (20.3e27.2%), the
increment was not statistically significant (pZ 0.14). Inter-
estingly, although ST239 isolates remained dominant, the
proportion of ST239 isolates declined significantly from 2006
to 2008 (pZ 0.03). As for the HA-MRSA isolates, Fig. 2 shows
the changes in the proportions of ST239, ST59, and ST5,
during the study period. Among the HA-MRSA isolates, the
proportion of ST239 declined significantly (pZ 0.007);
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Figure 2. The change in the proportion of ST239, ST59, and ST5, among health careeassociated methicillin-resistant Staphy-
lococcus aureus isolates, 2006e2008. STZ sequence type.
Stratified analysis by vancomycin MIC 349concurrently, the proportion of ST59 increased significantly
(pZ 0.005). Similarly, the proportion of ST5 did not change
during the 3-year period.Relationship between specific STs and vancomycin
MICs
Although all 470 isolates were susceptible to vancomycin
(MIC range, 0.5e2 mg/L), 81 isolates (17.2%) had a vanco-
mycin MIC of 2 mg/L. Most (65.5%) of the MRSA isolates with
a vancomycin MIC of 0.5 mg/L belonged to ST59, whereas
ST239 and ST5 isolates only accounted for 6.9% and 10.3%,
respectively. Among 81 MRSA isolates with a vancomycin
MIC of 2 mg/L, 73 (90.1%) belonged to ST239, whereas only
six, one, and one belonged to ST5, ST8, and ST241,
respectively. This finding implies that a higher proportion of
MRSA blood isolates with increased MICs (2 mg/L) of van-
comycin in this study may be because of the spread of the
predominant strain, ST239. Among MRSA isolates with
a vancomycin MIC of 2 mg/L, none of the ST59 isolates was
found. Table 2 summarizes the relationship between van-
comycin MICs and specific STs.Table 2 Relationship between specific STs and vancomy-
cin MICs
ST Range of vancomycin MICs
0.5 mg/L
(NZ 29)a
1 mg/L
(NZ 360)b
2 mg/L
(NZ 81)c
ST239, nZ 250 (%) 2 (6.9) 175 (48.6) 73 (90.1)
ST59, nZ 109 (%) 19 (65.5) 90 (25) 0
ST5, nZ 74 (%) 3 (10.3) 65 (18.1) 6 (7.4)
a Among 29 isolates, other STs belonged to ST1 (1 isolate),
ST45 (3 isolates), and ST537 (1 isolate).
b Among 360 isolates, other STs belonged to ST1 (3 isolates),
ST8 (3 isolates), ST30 (5 isolates), ST45 (5 isolates), ST78 (1
isolate), ST88 (1 isolate), ST537 (1 isolate), ST573 (8 isolates),
and ST900 (3 isolates).
c Among 81 isolates, other STs belonged to ST8 (1 isolate) and
ST41 (1 isolate).
MICZminimum inhibitory concentration; STZ sequence type.Relationship between vancomycin MICs and
susceptibilities to linezolid, tigecycline, and
daptomycin
All 470 isolates were susceptible to linezolid and tigecycline
(MIC range, 0.25e4 mg/L and 0.0125e0.5 mg/L, respec-
tively). Also, all but two isolates were susceptible to dap-
tomycin (MIC range, 0.125e4 mg/L). The susceptibility rate
to daptomycin was 99.6%. Among the 81 MRSA isolates with
a vancomycin MIC of 2 mg/L, all remained susceptible to
linezolid and tigecycline. Moreover, the susceptibility rate
of the isolates to daptomycin with a vancomycin MIC of
2 mg/L was 98.8% (MIC range, 0.25e4 mg/L). Table 3 shows
the relationship between vancomycin MICs and suscepti-
bilities to linezolid, tigecycline, and daptomycin of these
470 MRSA isolates.
Discussion
Based on our results, four important findings were dis-
closed. First, according to molecular epidemiology, ST239
(53.2%), ST59 (23.2%), and ST5 (15.7%) remained prevalent
among the MRSA blood isolates in our MRSA bacteremia
patients from January 2006 to December 2008, accounting
for 92.1% of all MRSA blood isolates. Second, the proportion
of ST239 isolates decreased significantly statistically. Third,
the proportion of ST59 isolates increased, although the
change was not statistically significant. However, the
proportion of MRSA isolate belonging to ST59 among all HA-
MRSA isolates increased significantly. The likelihood of ST59
replacing ST239 and then becoming the predominant strain
among all MRSA blood isolates deserves further epidemio-
logical studies in the future. Fourth, 17.2% of 470 MRSA
blood isolates expressed a high MIC level (2 mg/L) of van-
comycin. MRSA blood isolates having a high MIC (2 mg/L) of
vancomycin in this study may be because of the spread of
the predominant strain, ST239. Moreover, linezolid, tige-
cycline, and daptomycin remained highly active in vitro
against these MRSA blood isolates, even those with a van-
comycin MIC of 2 mg/L.2
CA-MRSA preferred to carry fewer antimicrobial resis-
tance genes, compared with HA-MRSA.21 Closely examining
Table 3 Relationship between vancomycin MICs and susceptibilities to linezolid, tigecycline, and daptomycin
Vancomycin
MICs (mg/L)
Range of MICs (susceptible, %)
Linezolid
(mg/L)
Tigecycline
(mg/L)
Daptomycin
(mg/L)
0.5 (NZ 29, 6.2%) 1e4 (100) 0.032e0.25 (100) 0.25e0.5 (100)
1 (NZ 360, 76.6%) 0.25e4 (100) 0.0125e0.5 (100) 0.125e2a (99.7)
2 (NZ 81, 17.2%) 0.25e4 (100) 0.032e0.5 (100) 0.25e4b (98.8)
a One isolate was nonsusceptible to daptomycin (MICZ 2 mg/L).
b One isolate was nonsusceptible to daptomycin (MICZ 4 mg/L).
MICZminimum inhibitory concentration.
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that most (65.5%) of the MRSA isolates with a vancomycin
MIC of 0.5 mg/L belonged to ST59, whereas ST239 isolates
constituted most (90.1%) of the MRSA isolates with a van-
comycin MIC of 2 mg/L. None of the ST59 isolates had a high
MIC (2 mg/L) of vancomycin. The likelihood that ST59
isolates become isolates with high vancomycin MICs in the
future, while responding to the selection pressure of
current antimicrobial agents in a hospital, requires
continuous surveillance.
Chen et al.6 indicated that ST239-SCCmec III (70.8%),
ST59-SCCmec IV/V (18.7%), and ST5-SCCmec II (4.7%)
accounted for most of the 257 MRSA bloodstream isolates in
our hospital from 1995 to 2006. Although ST239 isolates
prevailed over the previous 12-year period, the proportion
declined from more than 90% to 48%. Furthermore, the
proportion of ST59 and ST5 isolates increased concurrently.
Our study results reflected their finding that the proportion
of ST239 clones significantly decreased during the study
period. However, although ST59 clones increased during the
same period, the changes were not statistically significant.
The likelihood of ST59 strain replacing the traditional HA-
MRSA strain, ST239, to become the predominant strain
causing health careeassociated infections in the future
warrants further investigation.
Linezolid, tigecycline, and daptomycin may be the
therapeutic alternatives among patients with MRSA
bacteremia caused by an MRSA isolate with a vancomycin
MIC greater than or equal to 1.5e2 mg/L if based on just
the in vitro susceptibility test results.12,13 However, on the
basis of pharmacodynamic studies, tigecycline is not suit-
able to treat MRSA bacteremia for its low serum level and
bacteriostatic property.12 In addition, although some
studies showed that linezolid might not be inferior to van-
comycin in treating the outcomes of S aureus bacteremia,
linezolid also belongs to bacteriostatic agents.22 Therefore,
only daptomycin has been approved to treat S aureus
bacteremia by the U.S. Food and Drug Administration
among the three drugs till date.12,13 In this study, nearly all
MRSA blood isolates, even with a vancomycin MIC of 2 mg/
L, remained highly susceptible to daptomycin, except for
only two isolates (MICZ 2 mg/L and 4 mg/L). The result
indicated that daptomycin might be an optimal therapeutic
alternative to treat bacteremia caused by MRSA isolates,
even with a vancomycin MIC of 2 mg/L.
Despite its contributions, this study has certain limita-
tions. First, the study period is not sufficiently long to
observe a definite secular change; hence, continuoussurveillance is required to analyze the trend of molecular
epidemiology. Second, MRSA blood isolates were collected
from a single hospital. Interhospital differences may arise
concerning patients’ characteristics and antibiotic usage,
making the results inapplicable to other institutions.
In conclusion, our study demonstrated that the
proportion of MRSA isolates with a vancomycin MIC of
2 mg/L was 17.2% among MRSA blood isolates collected
from adult patients during January 2006 to December
2008. A significant proportion of MRSA blood isolates with
high MICs (2 mg/L) of vancomycin may be attributable to
the spread of the predominant strain, ST239. Addition-
ally, ST239 remained the predominant strain during the 3-
year period but with a significant trend to decrease.
Linezolid, tigecycline, and daptomycin remained highly
active against MRSA blood isolates, even though an
MRSA isolate had a vancomycin MIC of 2 mg/L. Howe-
ver, MRSA blood isolates require to be monitored
continuously to further analyze the fluctuating molecular
epidemiology and relationship between vancomycin MICs
and specific STs.
References
1. Ho M, McDonald LC, Lauderdale TL, Yeh LL, Chen PC, Shiau YR.
Surveillance of antibiotic resistance in Taiwan, 1998. J Micro-
biol Immunol Infect 1999;32:239e49.
2. Chamis AL, Peterson GE, Cabell CH, Corey GR, Sorrentino RA,
Greenfield RA, et al. Staphylococcus aureus bacteremia in
patients with permanent pacemakers or implantable car-
dioverter-defibrillators. Circulation 2001;104:1029e33.
3. Salmenlinna S, Lyytikinen O, Kotilainen P, Scotford R, Siren E,
Vuopio-Varkila J. Molecular epidemiology of methicillin-resis-
tant Staphylococcus aureus in Finland. Eur J Clin Microbiol
Infect Dis 2000;19:101e7.
4. Wang JT, Chen YC, Yang TL, Chang SC. Molecular epidemiology
and antimicrobial susceptibility of methicillin-resistant Staph-
ylococcus aureus in Taiwan. Diagn Microbiol Infect Dis 2002;
42:199e203.
5. Wang JT, Fang CT, Chen YC, Wu CL, Chen ML, Chang SC.
Staphylococcal cassette chromosome mec in MRSA, Taiwan.
Emerg Infect Dis 2007;13:494e7.
6. Chen CJ, Hsueh PR, Su LH, Chiu CH, Lin TY, Huang YC. Change
in the molecular epidemiology of methicillin-resistant Staph-
ylococcus aureus bloodstream infections in Taiwan. Diagn
Microbiol Infect Dis 2009;65:199e201.
7. D’Agata EM, Webb GF, Horn MA, Moellering Jr RC, Ruan S.
Modeling the invasion of community-acquired methicillin-
resistant Staphylococcus aureus into hospitals. Clin Infect Dis
2009;48:274e84.
Stratified analysis by vancomycin MIC 3518. Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS. Char-
acteristics of patients with healthcare-associated infection
due to SCC mec type IV methicillin-resistant Staphylococcus
aureus. Infect Control Hosp Epidemiol 2006;27:1025e31.
9. Popovich KJ, Weinstein RA, Hota B. Are community-associated
methicillin-resistant Staphylococcus aureus (MRSA) strains
replacing traditional nosocomial MRSA strains? Clin Infect Dis
2008;46:795e8.
10. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M,
Lomaestro BM, et al. Relationship between vancomycin MIC
and failure among patients with MRSA bacteremia treated with
vancomycin. Antimicrob Agents Chemother 2008;52:3315e20.
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-
dose vancomycin therapy for methicillin-resistant Staphylo-
coccus aureus infections: efficacy and toxicity. Arch Intern Med
2006;166:2138e44.
12. Micek ST. Alternatives to vancomycin for the treatment of
methicillin-resistant Staphylococcus aureus infections. Clin
Infect Dis 2007;45:S184e90.
13. Drees M, Boucher H. New agents for Staphylococcus aureus
endocarditis. Curr Opin Infect Dis 2006;19:544e50.
14. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ,
Etienne J, et al. Comparison of community- and health care-
associated methicillin-resistant Staphylococcus aureus infec-
tion. JAMA 2003;290:2976e84.
15. Seybold U, Kourbatova EV, Johnson JG, Halvosa SJ, Wang YF,
King MD, et al. Emergence of community-associated methi-
cillin-resistant Staphylococcus aureus USA300 genotype asa major cause of health care-associated blood stream infec-
tion. Clin Infect Dis 2006;42:647e56.
16. Wang JL, Wang JT, Chen SY, Hsueh PR, Kung HC, Chen YC, et al.
Adult methicillin-resistant Staphylococus aureus bacteremia in
Taiwan: clinical significance of non-multi-resistant antibiogram
and Panton-Valentine leukocidin gene. Diagn Microbiol Infect
Dis 2007;59:365e71.
17. Methods for dilution antimicrobial susceptibility tests for
bacteria that grow aerobically. Approved standard-seventh
edition, M7-A7. Wayne, PA: Clinical and Laboratory Standards
Institute; 2006.
18. Performance standards for antimicrobial susceptibility
testing. Nineteenth informational supplement, M100-S19.
Wayne, PA: Clinical and Laboratory Standards Institute; 2009.
19. The European Committee for Antimicrobial Susceptibility
Testing (EUCAST) Steering Committee. EUCAST technical note
on tigecycline. Clin Microbiol Infect 2006;12:1147e9.
20. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multi-
locus sequence typing for characterization of methicillin-
resistant and methicillin-susceptible clones of Staphylococcus
aureus. J Clin Microbiol 2002;38:1008e15.
21. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A,
et al. Genome and virulence determinants of high virulence
community-acquired MRSA. Lancet 2002;359:1819e27.
22. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin
for Staphylococcus aureus bacteraemia: pooled analysis of
randomized studies. J Antimicrob Chemother 2005;56:
923e9.
